Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15677610 | 0.84 | CARM1 (0.58) | CHRM3CHRM2CARM1PRMT6DRD2 | |
| SCHEMBL16579434 | 0.81 | CHRM2 (0.58) | CHRM3CHRM2CARM1PRMT6DRD2 | |
| SCHEMBL16215600 | 0.80 | CARM1 (0.57) | CHRM3CHRM2CARM1PRMT6DRD2 | |
| SCHEMBL23529265 | 0.78 | CHRM2 (0.58) | CHRM3CHRM2CARM1PRMT6 | |
| SCHEMBL21274124 | 0.77 | CARM1 (0.54) | CHRM3CHRM2CARM1PRMT6DRD2 | |
| SCHEMBL29669585 | 0.77 | CHRM2 (0.57) | CHRM3CHRM2CARM1PRMT6 | |
| SCHEMBL10262302 | 0.76 | SMN1; SMN2 (0.59) | CHRM3CHRM2CARM1PRMT6DRD3 | |
| SCHEMBL10261345 | 0.76 | SMN1; SMN2 (0.59) | CHRM3CHRM2CARM1PRMT6DRD3 | |
| SCHEMBL714763 | 0.76 | SMN1; SMN2 (0.59) | CHRM3CHRM2CARM1PRMT6DRD3 | |
| SCHEMBL10607825 | 0.76 | HRH3 (0.62) | CARM1PRMT6SMN1; SMN2GAAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | CHRM3 227/4885CHRM2 263/4885CARM1 1934/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | CHRM3 227/4885CHRM2 263/4885CARM1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.